International Immunology, Vol. 14, No. 11, pp. 1303-1311,
November 2002
© 2002 Japanese Society for Immunology
Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus
1 Center for Autoimmune Diseases, Department of Internal Medicine B, and 2 Department of Pathology, Sheba Medical Center, Tel Hashomer 52621, Israel 3 Research Institute of Rheumatic Diseases, Piestany, Slovakia
Correspondence to: Y. Shoenfeld; E-mail: shoenfel{at}sheba.health.gov.il
Transmitting editor: I. Pecht
Since the idiotypic network is an important mechanism for controlling the immune repertoire, we tested anti-idiotypic modulation employing concentrated specific natural polyclonal anti-double-stranded (ds) DNA anti-idiotypic antibodies obtained from a commercial IVIG in the treatment of experimental systemic lupus erythematosus (SLE). Specific natural polyclonal anti-dsDNA anti-idiotypic antibodies (IVIG-ID) were affinity purified from IVIG on an anti-dsDNA–Sepharose column constructed from anti-dsDNA idiotypes (ID) affinity purified from 55 patients with active SLE. NZB/W F1 mice were treated i.v. with 3 weekly injections of IVIG-ID (2 mg/kg/injection) or regular IVIG (400 mg/kg/injection) both before (age 8 weeks) and after developing anti-dsDNA antibodies at the age of 21–22 weeks. The IVIG-ID-treated mice showed a decline in the titer of anti-dsDNA antibodies during the treatment, reaching maximum suppression 1 week after the last injection. A significant difference in the proteinuria level in the IVIG-ID-treated group compared to the control group was observed. Immunohistology showed different patterns of IgG deposition, with mesangial and capillary wall deposits in controls and in the IVIG-treated group, but only mesangial deposits in the IVIG-ID-treated group. The survival time of the IVIG-ID-treated group was longer than the IVIG-treated group. Treatment with concentrated specific anti-dsDNA anti-ID prepared from commercial IVIG is more effective in suppressing the humoral reaction and clinical signs of SLE than native IVIG. These results point to the considerable regulatory role of anti-ID in the mechanism of action of IVIG in SLE.
Keywords: anti-DNA, anti-idiotype, i.v. Ig, NZB/W F1 mice, systemic lupus erythematosus
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G Zandman-Goddard, M Blank, and Y Shoenfeld Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside Lupus, September 1, 2009; 18(10): 884 - 888. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Damianovich, M. Blank, A. Raiter, B. Hardy, and Y. Shoenfeld Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg) Int. Immunol., September 1, 2009; 21(9): 1057 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Dussault, E. Ducas, C. Racine, A. Jacques, I. Pare, S. Cote, and S. Neron Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2 Int. Immunol., November 1, 2008; 20(11): 1369 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Perricone, C. De Carolis, B. Kroegler, E. Greco, R. Giacomelli, P. Cipriani, L. Fontana, and C. Perricone Comment on: Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion: reply Rheumatology, September 1, 2008; 47(9): 1439 - 1440. [Full Text] [PDF]
|
|
|
|
|
|
R. Perricone, C. De Carolis, B. Kroegler, E. Greco, R. Giacomelli, P. Cipriani, L. Fontana, and C. Perricone Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion Rheumatology, May 1, 2008; 47(5): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kessel, H. Ammuri, R. Peri, E. R. Pavlotzky, M. Blank, Y. Shoenfeld, and E. Toubi Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function J. Immunol., October 15, 2007; 179(8): 5571 - 5575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Blank, L. Anafi, G. Zandman-Goddard, I. Krause, S. Goldman, E. Shalev, R. Cervera, J. Font, M. Fridkin, H.-J. Thiesen, et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model Int. Immunol., July 1, 2007; 19(7): 857 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shoenfeld, R. Wu, L. D. Dearing, and E. Matsuura Are Anti-Oxidized Low-Density Lipoprotein Antibodies Pathogenic or Protective? Circulation, October 26, 2004; 110(17): 2552 - 2558. [Full Text] [PDF]
|
|